Tesla shares fall nearly 5% in extended trade after negative free cash flow in Q2

During the quarter, Tesla sold more low-cost versions of the Model 3 and Model Y, after retiring its more expensive flagship models “S” and “X.”

During the quarter, Tesla sold more low-cost versions of the Model 3 and Model Y, after retiring its more expensive flagship models “S” and “X.”

In a post-earnings interaction with CNBC-TV18, the management of Dr. Reddy’s said that it is not practical to move manufacturing operations to the US and they will await more clarity on the subject as this is just a social media…

Alphabet’s net income also surged courtesy of the gains from its investments made in Anthropic and SpaceX. The other income component itself contributed nearly $100 billion to its net income during the quarter.

Shares of Power Grid Corporation of India Ltd ended at ₹288.30, up by ₹1.65, or 0.58%, on the BSE.

Indian investors will closely monitor US market trends, developments in the US-Iran conflict, and key US economic data for directional cues. Oil prices have surged to fresh highs as concerns over supply disruptions persist, even as the US and Iran…

Shares of Tanla Platforms Ltd ended at ₹565.80, down by ₹0.80, or 0.14%, on the BSE.

Revenue from operations rose 53% year-on-year to ₹924 crore during the quarter, while EBITDA increased 48% to ₹173 crore. Company’s EBITDA margin stood at 18.8%, compared with 19.5% in the corresponding quarter last year.

OFSS profit jumped 68.2% to ₹1,416 crore in Q1FY27, revenue up 51.3% to ₹3,125 crore, driven by a one-off deal. Makarand Padalkar resigned, Avadhut Ketkar is new CEO.

Gandhar Oil Refinery reported a sharp sequential improvement in its June quarter performance, with standalone profit rising to ₹179 crore as revenue climbed 71.2%. EBITDA margin expanded to 15.7% from 7% in the previous quarter.

The ADR is currently trading at $11.90, down $0.67 from the previous close. The company’s quarterly performance was impacted by provisions related to the semaglutide ingredients issue and a decline in generics revenue in North America.